within Pharmacolibrary.Drugs.D_Dermatologicals.D06B_ChemotherapeuticsForTopicalUse.D06BB03_Aciclovir;

model Aciclovir
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.2,
    Cl = 4.333333333333333e-06,
    adminDuration = 600,
    adminMass = 400 / 1000000,
    adminCount = 1,
    Vd = 0.00067,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.014,
    Tlag = 0,
    Vdp = 0.00053,
    k12 = 5.0555555555555555e-06,
    k21 = 5.0555555555555555e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Aciclovir</td></tr><tr><td>ATC code:</td><td>D06BB03</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>400</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.67</td><td>L</td></tr>
    <tr><td>clearance:</td><td>260</td><td>ml/min/1.73m2</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Aciclovir is an antiviral medication primarily used for the treatment of infections caused by herpes simplex virus and varicella zoster virus, including genital herpes, cold sores, shingles, and chickenpox. It is available under prescription and remains an approved and commonly used antiviral drug globally.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after single oral dose of 400 mg aciclovir.</p><h4>References</h4><ol><li><p>O&#x27;Brien, JJ, &amp; Campoli-Richards, DM (1989). Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. <i>Drugs</i> 37(3) 233–309. DOI:<a href=\"https://doi.org/10.2165/00003495-198937030-00002\">10.2165/00003495-198937030-00002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2653790/\">https://pubmed.ncbi.nlm.nih.gov/2653790</a></p></li><li><p>Patel, R (1997). Valaciclovir: development, clinical utility and potential. <i>Expert opinion on investigational drugs</i> 6(2) 173–189. DOI:<a href=\"https://doi.org/10.1517/13543784.6.2.173\">10.1517/13543784.6.2.173</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15989601/\">https://pubmed.ncbi.nlm.nih.gov/15989601</a></p></li><li><p>Noble, S, &amp; Faulds, D (1998). Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. <i>Drugs</i> 56(1) 115–146. DOI:<a href=\"https://doi.org/10.2165/00003495-199856010-00012\">10.2165/00003495-199856010-00012</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9664203/\">https://pubmed.ncbi.nlm.nih.gov/9664203</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.D.D06BB03 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Aciclovir;
